Aquestive Therapeutics, Inc.
AQST Healthcare Drug Manufacturers Specialty & Generic
Aquestive Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, down 22.6% from fiscal 2024. In the quarter to June 2026, revenue grew 38.2%, EPS fell 28.6%, free cash flow fell 20.4% and total debt rose 59.1%, each against the same quarter a year earlier.
Follow AQST
Aquestive Therapeutics, Inc. (AQST) EV/Sales
As of 16 October 2026, Aquestive Therapeutics, Inc. (AQST) trades at a EV/Sales of 7.9×. Over the past ten years it has ranged from 0.9× (March 2023) to 16.8× (October 2025); the current reading is higher than 87% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.4× | 186.09% |
| FY2024 | 4.7× | 86.97% |
| FY2023 | 2.5× | 138.80% |
| FY2022 | 1.0× | (68.92%) |
| FY2021 | 3.4× | (15.19%) |
| FY2020 | 4.0× | 32.09% |
| FY2019 | 3.0× | 80.55% |
| FY2018 | 1.7× | (63.15%) |
| FY2017 | 4.5× | 0.00% |
| FY2016 | 4.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.7× | 3.69% |
| Mar 2026 | 8.4× | (37.20%) |
| Dec 2025 | 13.4× | 12.07% |
| Sep 2025 | 12.0× | 75.90% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. compare | 0.6× |
| EVO Evotec AG compare | 0.6× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| KMDA Kamada Ltd. compare | 2.1× |
| EOLS Evolus, Inc. compare | 2.1× |
| COLL Collegium Pharmaceutical, Inc. compare | 2.1× |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 2.8× |
| AQST Aquestive Therapeutics, Inc. | 7.9× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)